dsm-firmenich Unveils CBtru, Transforming CBD Drug Development with Improved Bioavailability

The IP-protected CBD intermediate delivers enhanced functionality, enabling higher drug loading than currently available products. This innovation paves the way for oral dosage forms with improved bioavailability, facilitating the development of more convenient and patient-friendly forms such as tablets, orally disintegrating tablets (ODTs), or chewables. Named CBtru, this advancement represents a significant leap in cannabinoid innovation, with the potential to transform CBD-based therapies.

Pioneering a New Frontier in CBD Drug Development

Current CBD-based medications face challenges in terms of oral bioavailability, which can be as low as 6% in humans. This low bioavailability limits their efficacy due to the poor solubility and absorption of cannabinoid molecules. As a result, large doses of CBD are needed for therapeutic effectiveness, often necessitating oil-based oral solutions which can be inconvenient and unpleasant for patients. dsm-firmenich’s advanced formulated CBD drug product intermediate seeks to address this issue by allowing for higher active loading, improved stability, and optimized pharmacokinetic performance. These improvements enable the creation of more bioavailable and patient-friendly dosage forms.

A Molecule with Immense Therapeutic Potential

“We are committed to improving global patient health by unlocking new treatment possibilities and enhancing product acceptance and compliance. That’s why we have invested in CBD – a molecule that holds immense therapeutic potential, as evidenced by promising research and a favorable regulatory environment,” said Athanasia Kanli, global business development manager for pharma at dsm-firmenich. Despite the promising therapeutic potential, the application of CBD has been largely limited to oil-based delivery systems due to its low bioavailability and instability. This limitation inspired the development of CBtru, which aims to introduce more efficient and patient-friendly treatments to the expanding cannabinoid market.

The Result of Two Years of Focused Research

The creation of dsm-firmenich’s novel CBD drug product intermediate is the culmination of two years of intensive research. During this period, the company’s technical team rigorously evaluated over 200 prototypes and numerous drug delivery technologies to identify a CBD solution with superior performance. Moving forward, dsm-firmenich plans to establish long-term strategic partnerships to explore new therapeutic applications leveraging its trial-ready CBtru formulation.

Beyond CBtru

In collaboration with Brains Bioceutical – a manufacturer of high-quality pharma-grade cannabinoids – dsm-firmenich offers a comprehensive innovation platform designed to support early-stage cannabinoid drug development and realize the potential of CBD-based formulations. Their capabilities include cutting-edge formulation expertise, a global network of regulatory specialists, and proficiency in preclinical and clinical studies. The company is also equipped to provide customized solutions depending on the therapeutic area and drug delivery objective.

Through these efforts, dsm-firmenich aims to revolutionize the treatment landscape for CBD-based medicines, making therapies more effective, patient-friendly, and widely accepted. The introduction of CBtru marks a significant advancement in the field, promising to enhance the therapeutic potential and patient experience of CBD-based treatments.